This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

The Effectiveness of Combining Lithium With Olanzapine in the Treatment of Resistant Schizophrenia

Joaquí­n C. Martí­n, Ginés Palenciano, and Rocio Perez

Published: December 31, 2000

Article Abstract

Letter to the Editor

Sir: The Expert Consensus pane1 agrees that adding lithium to conventional antipsychotics for treating resistant schizophrenia can be a second-line alternative, although a recent trial found no response with lithium augmentation. This combination can improve both psychotic and affective symptoms. Olanzapine is a new, atypical antipsychotic medication that seems effective and safe in the treatment of schizophrenia. Two open-label clinical trials also suggest good results with olanzapine in individuals with resistant schizophrenia. Nevertheless, 1 doubleblind comparison trial obtained contrasting results in terms of effectiveness. We present our experience with 5 treatment-resistant schizophrenic patients (DSM-IV criteria) who did not respond to olanzapine as monotherapy, but did exhibit improvements when lithium was added to the treatment.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 61

Quick Links: Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...